MeCure Industries Plc, a Nigerian pharmaceutical company, held its 2nd Annual General Meeting (AGM) on October 3, 2025, at the Oriental Hotel in Lagos.
The meeting, which was attended by shareholders, resulted in the approval of several important resolutions that will shape the company’s future.
The AGM commenced with the adoption of the Directors’ Report and the Audited Financial Statements for the year ending December 31, 2024, along with the Reports from the Auditors and the Audit Committee.
Shareholders also approved a dividend of N0.15 per ordinary share of 50 kobo, a decision well received by investors.
In a key governance update, retiring directors Dr. Benedict Ago and Mr. Chidi Oko were re-elected by rotation. The company appointed Messrs. Olutunji Cole & Co. as the new External Auditors, replacing Olagoke & Co., and authorized the directors to determine their remuneration.
The renewal of the Managers’ appointments was also approved.
The Statutory Audit Committee saw new appointments, with Mr. Tunji Bamidelu, Mrs. Samit Odumosu, and Mrs. Yakubu Titilayo Mosuro joining existing members, including Mr. Chidi Oko (Chairman) and Mr. Joseph Babatunde. The re-appointment of Non-Executive Directors for the 2025 financial year was also approved.
To ensure operational flexibility, shareholders authorized routine transactions with related parties on normal commercial terms, in accordance with Nigerian Exchange Limited rules.
Administrator and Writer
